Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists

Journal of Occupational and Environmental Medicine

Volumn 39, Issue 6, 1997, Pages 574-580

  Valanis, Barbara ^a   Vollmer, William ^a   Labuhn, Karen ^a   Glass, Andrew ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; MALE; NURSE; OCCUPATIONAL EXPOSURE; PHARMACIST; PROTECTIVE EQUIPMENT; QUESTIONNAIRE; SELF REPORT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; INFERTILITY; LOGISTIC MODELS; MALE; MIDDLE AGED; NURSES; OCCUPATIONAL EXPOSURE; ODDS RATIO; PHARMACISTS;

EID: 0030927614     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199706000-00013     Document Type: Article

References (30)

1. Selevan S, Lindbohm M, Hornung K, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985;313: 1173-1177.
2. Hemminki K, Kyyronen P, Lindbohm M. Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985;39: 141-7.
3. Taskinen HK. Effects of parental occupational exposures on spontaneous abortion and congenital malformation. Scand J Work Environ Health. 1990;16:297-314.
4. Stucker I, Caillard JF, Collin R, Gout M, Poyen D, Hemon D. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health. 1990;16:102-107.
5. Skov T, Maarup B, Olsen J, Rorth M, Winthereik H, Lynge E. Leukemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992;49:855-861.
6. McDonald AD, McDonald JC, Armstrong B, et al. Congenital defects and work in pregnancy. Br J Ind Med. 1988; 45:581-588.
7. Calabresi P, Parks RE Jr. Chemotherapy of neoplastic diseases. In: Gilman AG, Goodman LS, Gelman A, eds. The Pharmacological Basis of Therapeutics, 6th ed. New York: MacMillan; 1980:1249-1255.
8. McDiarmid MA, Kolodner K, Humphrey F, Putman D, Jacobson-Kram D. Baseline and phosphoramide mustard-induced sister-chromatid exchanges in pharmacists handling anti-cancer drugs. Mutat Res. 1992;279:199-204.
9. Jacobson-Kram D, Albertini RJ, Branda RF, et al. Measurement of chromosomal aberrations, sister chromatid exchange, hprt mutations, and DNA adducts in peripheral lymphocytes of human populations at increased risk for cancer. Environ Health Perspect. 1993;101(suppl):121S-125S.
10. US Dept of Labor, Occupational Safety, and Health Administration. Controlling occupational exposure to hazardous drugs. OSHA Technical Manual [section V, chapter 3]. 1995, Washington, DC: OSHA; 1995.
11. Selevan SG, Lemasters GK. The dose response fallacy in human reproductive studies of toxic exposures. J Occup Med. 1987;29:451-454.
12. Fody EP, Walker EM. Effects of drugs on the male and female reproductive systems. Ann Clin Lab Sci. 1985;15:451-458.
13. Waxman J. Cancer, chemotherapy, and fertility. BMJ. 1985;290:1096-1097.
14. Romagnolo D, Marchesoni D, Maggino T. Antiblastic chemotherapy and reproductive life. Clin Exp Obstet Gynecol. 1988;15:38-46.
15. Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin. 1990;40:199-209.
16. Rustin GJ, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumors. BMJ. 1984;288: 103-106.
17. Wilcox A, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319:190-194.
18. Shortridge L, LeMasters G, Valanis B, Hertzberg V. Menstrual cycles in nurses handling antineoplastic drugs. Cancer Nurs. 1995;18:439-444.
19. Sobrinho LG, Levine RA, DeConti RC. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol. 1971;109: 135-139.
20. Warne GL, Gairley KF, Hobbs JB, Martin FR. Cyclophosphamide induced ovarian failure. N Engl J Med. 1973;289: 1159-1162.
21. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin's disease: I. Hormone function. JAMA. 1979;245:1877-1881.
22. Uldall PR, Kerr DNS, Tacchi C. Sterility and cyclophosphamide. Lancet. 1972;1: 693-694.
23. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet. 1977;1:1174-1176.
24. Horning SJ, Hoppe RJ, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med. 1981;304:1377-1382.
25. Valanis B, Vollmer W, Labuhn K, Glass A, Corelle C. Cytotoxic drug handling protection after OSHA guidelines: comparison by profession, handling activity, and work site. J Occup Med. 1992;34: 149-155.
26. Labuhn KT, Valanis BG, Glass AG, Vollmer WM. Implementing a cancer control study in an NCI Clinical Trials Network. J Cancer Pract. 1994;2:47-54.
27. Valanis B, Vollmer W, Labuhn KT, Glass A. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993;50:455-462.
28. Valanis BV, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 1993;16:288-295.
29. EGRET Manual (Epidemiological Graphics. Estimation, and Testing package) Analysis Module (PECAN), version 0.25.6, and EPIXACT, version 0.03. (1985-1991). Seattle, WA: Statistics and Epidemiology Research Corp and Cytel Software Corp; 1992.
30. National Center for Health Statistics, Mosher WD, Pratt WF. Reproductive impairments among married couples: United States. Vital Health Stat. [23]. 1982;11:3.